SEQUENTIAL TOPOTECAN & ETOPOSIDE FOR PATIENTS WITH MYELOID LEUKEMIA

本研究的目的是确定该药的毒性和有效性。 拓扑替康连续静脉滴注72小时，然后每日 复发或难治性急性髓系白血病患者的依托泊苷。 目标是确定最大耐受量，并描述 毒性。 已有8名患者入选。7名患者的生活质量没有变化。 一名患者在医生的酌情决定下被取消了研究。 患者目前正在接受剂量水平为2的治疗。试验将 继续招收病人。

The purpose of this study is to determine the toxicity and efficacy of sequential topotecan administered as a 72 hour infusion followed by daily etoposide in patients with relapsed or refractory acute myeloid leukemia. The objectives are to determine the maximum tolerated dose and to describe the toxicity. Eight patients have been enrolled. Seven patients had no change in their disease and one patient was taken off study at the physician's discretion. Patients are currently being treated at dose level 2. The trial will continue to accrue patients.